Cladribine, cytarabine, and GCSF with and without mitoxantrone (CLAG ± M) is highly effective for poor risk acute myeloid leukemia with adverse karyotype and prior hypomethylating therapy

Abstract

The regimen of cladribine, cytarabine, and filgrastrim with mitoxantrone (CLAG-M, GCLAM) has shown significant promise for upfront therapy of secondary acute myeloid leukemia (now known as AML with...